$CC

CRANSTON MARY B purchased $95K of CC

CRANSTON MARY B purchased 6,000 shares of Chemours Co (CC) at $15.82 on 2026-08-07.

Original reporting
SEC EDGAR · CRANSTON MARY B
Published Aug 11, 2026, 8:10 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 11, 2026, 9:06 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$CC
Neutral
low confidence
Mentioned
$CC
Relevance
4/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CCNeutralLow
01

Why it matters

A director’s open-market purchase is a mild positive sentiment input, but the filing alone does not change Chemours’ fundamentals or near-term expectations.

02

Market read

Traders may note the insider buy as a small sentiment signal, but there is no new operational or financial catalyst in the text.

03

What to watch

Insider buys are often less informative without context such as prior trading patterns, option exercises, or concurrent company-specific catalysts.

Relevance 4/10Novelty 3/10Timing: Form 4 filed 2026-08-11, covering a purchase dated 2026-08-07.

Background

The article is an SEC Form 4 insider transaction disclosure for Chemours Co (CC).

Company-level read

Ticker impact

$CCNeutralLow confidence
Context

Chemours Co director Mary B Cranston bought 6,000 shares of CC for about $94,950 on 2026-08-07, disclosed via Form 4 filed 2026-08-11.

Expected impact

Likely limited immediate impact; any effect would be sentiment-driven and short-lived.

Evidence & confidence

Form 4 insider buys can be read as confidence signals, but the article provides no accompanying guidance, contract, legal, or operational catalyst, and the transaction size is modest relative to typical market-moving events.

Market effects

No sector-level read-through is provided beyond a single-company insider transaction.

None indicated.

None indicated.

Counterpoint

The purchase may reflect diversification or personal liquidity needs rather than a forward-looking view, especially since the filing does not include a 10b5-1 plan.

Key entities

  • Chemours Co

    Subject of the Form 4 insider transaction disclosure.

  • CRANSTON MARY B

    Director who purchased 6,000 shares of CC at $15.8250/share.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$CCMed

Why Chemours Plunged on Wednesday

Chemours (NYSE: CC) shares fell 18.7% after its Q2 earnings. The company reported slight revenue decline and adjusted EPS of $0.42, down 31% year over year, meeting expectations. Management cited lower Optane refrigerant sales due to supply-chain inventory and the wind-down of the SPS Capstone business. Full-year growth guidance remains 1% to 5%.

$CCMed

Why Chemours Plunged on Wednesday

Chemours (NYSE: CC) shares fell 18.7% after the company reported Q2 results. Revenue edged down and adjusted EPS fell 31% to $0.42, missing expectations. Lower Optane refrigerant sales and the prior wind-down of the SPS Capstone business weighed on results. Chemours still forecasts full-year growth of 1% to 5%.

$CCMedAI 8/10

The Chemours Company Reports Second Quarter Results

Chemours (NYSE: CC) reported Q2 2026 results: net sales about $1.6B, roughly flat year over year. Net loss attributable to Chemours was $274M ($1.81 per diluted share) versus $380M ($2.53) a year earlier. Adjusted net income was $64M ($0.42) and adjusted EBITDA $247M. Free cash flow rose 128% and net leverage fell to 4.4x. Chemours cited TiO2 pricing actions and APM Performance Solutions growth.

$CCMed

Chemours Co (CC): Results of Operations and Financial Condition

Chemours Co (CC) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 cc-ex99_1.htm EX-99.1 EX-99.1 EXHIBIT 99.1 The Chemours Company Reports Second Quarter Results Wilmington, Del., August 4, 2026 – The Chemours Company (“Chemours” or “the Company”) (NYSE: CC), a global chemistry company with leading market positions in Thermal & Special

$MMMHighAI 9/10

New York sues 3M, DuPont and other chemical companies over PFAS pollution By Investing.com

New York Attorney General Letitia James sued 3M, DuPont, Chemours, Corteva and EIDP over alleged PFAS (“forever chemicals”) contamination. The complaint says the firms knew since decades-old research that PFAS were toxic but concealed risks, continued selling PFAS products, and allegedly misled consumers. New York seeks cleanup funding, consumer warnings, advertising changes, and damages and penalties.